Method for Recovery and Immunoaffinity Enrichment of Membrane Proteins Illustrated with Metastatic Ovarian Cancer Tissues

Table 2

Salient details of the proteins studied by western blots (Figure 2) and their estimated recoveries following the new method using ProteoSolve-TD2 buffer.

Database accession number	Protein name	Number of transmembrane sequences	Gene name(s)	Predicted sequence MW(s)	Apparent MW(s)	Estimated recovery (ProteoSolve-TD2)
Q9HBW0	Lysophosphatidic acid receptor 2	7	LPAR2; EDG4; LPA2	39 kDa	50 kDa [43]	65%
Q92633	Lysophosphatidic acid receptor 1	7	LPAR1 EDG2	41 kDa	43 kDa [44]	90%
Q0VHD7	CD95 ligand	1	FASLG	31 kDa	40 kDa [45]	95%
O14786	Neurophilin-1 (CD304)	1; 0	NRP1; VEGF165R	103 kDa; 72 kDa	130–140 kDa [46]	95%
P35968	Vascular endothelial growth; factor receptor 2 (CD309)	1	KDR; FLK1	150 kDa	150 kDa; 200 kDa; 230 kDa [47]	90%
P08962	Lysosomal-associated membrane protein 3 (CD63)	4	Tspan-30; LAMP-3	26 kDa	53 kDa [48]	100%
P10415	Apoptosis regulator Bcl-2	1; 0	BCL2	26 kDa; 22 kDa	28 kDa [49]	see text
O96020	Cyclin-E2 (G1/S specific)	0	CCNE2	47 kDa; 41 kDa	45 kDa [50]	100%
P51654; Q53H15; Q2L882; Q2L880	Glypican-3	Lipid anchored; 0	GPC3	66 kDa; <66 kDa	65 kDa [51–53]	60%
P31749; P3175; Q9Y243	RAC serine/threonine-protein kinases 𝛼,𝛽,𝛾	0	AKT; PKB; RAC	56 kDa; 54 kDa	58 kDa [54]	95%
Q6P602; Q9H4B7; Q13885; Q9BVA1; Q9BUF5; P68371; Q13509; Q2NKY5; Q3ZCM7	𝛽-tubulin	0	TUBB [55]	50 kDa	50 kDa [56]	95%